Affective Disorders Flashcards
(46 cards)
Depression screening
PHQ-9
0-4 - non to minimal
5-9 - mild
10-14 - moderate
15-19 - moderately severe
20-27 - severe
Depression core management
Assessment and Monitoring
Psychoeducation and Self -Help - mild
Medication - moderate or severe
Psychological therapy - moderate or severe
Combined treatment - medicine and therapy for severe
Long term management
Mild to moderate depression management
Low-Intensity Psychosocial Intervention 6-8 sessions
Computerised CBT
Structured group physical activity programme
Moderate to severe depression management
Medication
- SSRI (sert)
Drug interaction - fluox, fluvoxamine, paroxetine
Discontinuation symptoms - paroxetine
Death from overdose - venlafaxine
Overdose - TCA
BP monitoring needed - venlafaxine
Postural hypotension and arrhythmia
Review after 2 weeks
18-25 or high risk review after 1 week
High-intensity psychological intervention - individual CBT, interpersonal therapy
Complex and severe depression management
Crisis resolution and home treatment teams to manage crises
Develop a crisis plan that identifies potential triggers and strategies to manage triggers
Consider inpatient treatment if significant risk of suicide, self-harm or neglect
Consider ECT for acute treatment of severe depression when:
- It is life-threatening and rapid response is required
- Other treatments have failed
- When there is evidence it has worked for the patient in the past
Switching antidepressants
Fluoxetine to other - 4-7 day washout period before staring another SSRI
Fluoxetine or Paroxetine to TCA - lower starting dose of TCA recommended to reduce serotonin syndrome
To new serotonergic antidepressant or MAOI - caution due to serotonin syndrome
From non-reversible MAOI - 2 week washout period
Mania and BPAD core management
Medication - mood stabiliser and antipsychotics for acute episodes. avoid antidepressant without mood stabiliser sue to risk of mania
Psychological intervention - psychoeducation, CBT, family focused intervention
Physical health monitoring - weight, BP
Crisis planning
Mood stabilisers (Mania/BPAD)
Stabilise the extreme highs of mania and profound lows of depression
More effective against mania
Three main drugs:
o Lithium
o Sodium valproate
o Carbamazepine
Mechanism of action is uncertain (possibly to do with sodium channels or GABA)
Lithium
Therapeutic range: 0.6-1.0 mmol/L
- 0.6-0.8 is suitable for patients who are lithium-naïve
- 0.8-1.0 is suitable for patients with chronic/long-term lithium use or who have had a relapse in symptoms
Becomes toxic from 1.5mmol/L, with severe toxicity above 2mmol/L
Measure BMI, check FBC. U&Es and TFTs before starting
Plasma lithium levels should be checked 1 week after starting or changing dose and monitored weekly until a steady therapeutic level is achieved (aiming for 0.6-0.8 mmol/L)
Blood sample should be taken 12 hour after taking dose of lithium
It should be monitored every 3 months from then on
U&Es and TFTs should be monitored every 6 months (can cause renal impairment and hypothyroidism)
Lithium toxicity
Symptoms:
- Coarse tremors
- Polyuria
- Seizures
Triggers:
- salt balance and electrolyte changes
- drugs interfering with lithium
- accidental or deliberate overdose
Lithium toxicity management
Check lithium level
Stop lithium dose
- Warning: stopping lithium abruptly could precipitate symptoms of mania/depression
Transfer for medical care (rehydration, osmotic diuresis)
If overdose is severe, the patient may need gastric lavage or dialysis
Sodium valproate (Mania/BPAD)
Treats acute mania
Prophylaxis in BPAD
Given as sodium valproate because of reduced side effects
Check BMI, FBC and LFTs before starting
Carbamazepine (Mania/BPAD)
Can cause toxicity at high doses
Induces liver enzymes
Close monitoring of carbamazepine levels is essential
Check for drug interactions before prescribing
Mood stabiliser during pregnancy
Mood stabilisers are teratogenic
Risk of harm to fetus should be weighed against harm of manic relapse
Lithium - Ebstein’s anomaly
Valproate and carbamazepine - spina bifida
- Women of childbearing age should have a pregnancy prevention programme
in place
- Do not start valproate for the first time in people younger than 55 years
Closely monitor the foetus if mood stabilisers are used in pregnancy
Antiosychotics (Mania/BPAD)
Olanzapine
Usually atypical (e.g. olanzapine, risperidone, quetiapine) because of fewer side-effects
Before starting, check BMI, pulse, BP, fasting blood glucose or HbA1c, lipid
profile
Anticonvulsants (Mania/BPAD)
Lamotrigine is 2nd line for prophylaxis in BPAD type II
Check FBC, U&Es and LFTs before starting
Acute treatment of Mania or hypomania
Stop all medications that may induce symptoms (e.g. anti-depressants, recreational drugs, steroids and dopamine agonists)
If not currently on treatment
- Give an antipsychotic and a short course of benzodiazepines
If already on treatment
- Optimise the medication
- Consider adding another medication (e.g. antipsychotic added to mood stabiliser)
- Short-term benzodiazepines may help
ECT may be used if patients are unresponsive to medication
Mania and BPAD long term management
Mood stabilisers
Depression in BPAD
- Difficult because antidepressants can cause a switch to mania
- To reduce this risk, antidepressants should only be given with a mood
stabiliser or antipsychotic
- 1st line: fluoxetine + olanzapine/quetiapine
- 2nd line: lamotrigine
- Monitor closely for signs of mania and immediately stop antidepressants if signs are present
Psychological treatment
CBT
Psychodynamic psychotherapy
Opioid overdose
Naloxone
Decrease intestinal absorption of antidepressants
Activated charcoal
Paracetamol overdose
N-acetylcysteine
Follow up intervention following SH or suicide attempt
Within 1 week of SH or discharge
Psychosis/Schizophrenia screening
Brief Psychiatric Rating Scale
<31: Minimal symptoms
31–40: Mildly symptomatic
41–53: Moderately symptomatic
54+: Marked to severe symptoms, often indicating the need for more intensive
treatment.